Published 8 days ago • loading... • Updated 8 days ago

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Summary by Financial Post

“Building upon more than 700+ patient-years of data to date, we are excited to share our 36-month azetukalner data from our ongoing X-TOLE open-label extension study in FOS showing sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and a consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner,” stated Dr. Christopher Kenney, Chief Medical Officer of Xenon. “We are also presentin…

4 Articles

All

Left

Center

Right

Orangeville

+3 Reposted by 3 other sources

Lean Left

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures (FOS)Exploratory analysis of efficacy of azetukalner in FOS seizure sub-typesPatient…

8 days ago·Orangeville, Canada

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year